Currently, AD does not have a cure, and confirmatory diagnostics is postmortem; however, some potential biomarkers in CSF were proposed for the diagnosis of AD, such as the presence of total tau protein (T-tau) and hyperphosphorylated tau (P-tau 181 and P-tau 217), the relationship between amyloid beta 42/40 peptides, and the presence of neurofilament light protein (NfL) [28,29,30]. The gene discussed is MAPT; the disease is Alzheimer disease.